RxDoctor Payments Data

Vanessa Santana

Family · Lebanon, TNNPI 1205193794

Payments from drug & device makers

$1,200in general payments, 2019–2025

Across 79 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$308
  • Novo Nordisk$175
  • AstraZeneca$123
  • AbbVie$120
  • Bayer$110
  • Boehringer Ingelheim$88
  • plus $275 from 13 others

What the payments were for

  • Food & beverage$1,200100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,200 in reported general payments places this provider in the 65th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$82,587
Medicare patients
239
Services billed
1,435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$130,834
TrulicityDulaglutide29$69,825
JardianceEmpagliflozin48$59,213
OzempicSemaglutide34$49,742
RybelsusSemaglutide23$44,678
JanuviaSitagliptin Phosphate23$36,787
EliquisApixaban38$35,738
Tresiba Flextouch U-200Insulin Degludec28$28,749
XareltoRivaroxaban12$19,197
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,084
MyrbetriqMirabegron21$14,827
SymbicortBudesonide/Formoterol Fumarate23$6,916
Atorvastatin Calcium491$4,615
Levothyroxine Sodium387$4,424
Famotidine207$3,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$308$200,659111 claims
Novo NordiskOzempic, Rybelsus$175$94,42057 claims
Boehringer IngelheimJardiance$88$59,21348 claims
GSKTrelegy Ellipta, Arnuity Ellipta$14$21,71138 claims
Johnson & JohnsonXarelto$26$19,19712 claims
Astellas Pharma US IncMyrbetriq$23$14,82721 claims
AstraZenecaSymbicort$123$6,91623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 6,706 family providers in Tennessee.

Other family in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →